NKGen Biotech RGB.jpg
NKGen Biotech Announces Appointment of Steven Cha, MD as Chief Medical Officer
April 15, 2021 08:30 ET | NKGen Biotech, Inc.
SANTA ANA, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech RGB.jpg
NKMax and Merck KGaA, Darmstadt, Germany Expand Clinical Collaboration to Include Phase I/IIa Trial Investigating the Combination of SNK01 with ERBITUX® (cetuximab) in Metastatic NSCLC
April 13, 2021 09:30 ET | NKGen Biotech, Inc.
SEOUL, South Korea, April 13, 2021 (GLOBE NEWSWIRE) -- NKMax, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies,...
NKGen Biotech RGB.jpg
NKGen Biotech Announces Appointment of Philip Moody as Chief Financial Officer
April 07, 2021 09:00 ET | NKGen Biotech, Inc.
SANTA ANA, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- NKGen Biotech, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKGen Biotech RGB (002).jpg
NKMax America Announces Corporate Name Change to NKGen Biotech
April 02, 2021 06:30 ET | NKGen Biotech, Inc.
SANTA ANA, Calif., April 02, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKMAX_AMERICA-300x215.png
NKMax America Announces Key Leadership Appointment
February 04, 2021 08:00 ET | NKMax America
SANTA ANA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKMAX_AMERICA-300x215.png
Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy
October 20, 2020 06:30 ET | NKMax America
Proof of Concept study to establish safety and recommended dose of Affimed’s innate cell engager (ICE®) AFM24 in combination with NKMax America’s Natural Killer (NK) cells in solid tumorsPre-clinical...
NKMAX_AMERICA-300x215.png
NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
September 08, 2020 19:00 ET | NKMax America
SANTA ANA, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKMAX_AMERICA-300x215.png
NKMax America Receives FDA Clearance to Amend its Current Phase I Monotherapy Trial to Include an Additional New Cohort of SNK01 + Checkpoint Inhibitor in Refractory Solid Tumors
August 31, 2020 14:21 ET | NKMax America
SANTA ANA, Calif., Aug. 31, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's innate immune system through the development of Natural Killer (NK)...
NKMAX_AMERICA-300x215.png
NKMax America Receives FDA Clearance of IND for Phase I/2a Trial of their Natural Killer Cell Therapy (SNK01) in Combination with Trastuzumab or Cetuximab for the Treatment of Advanced/Metastatic HER2- or EGFR- Expressing Cancers
June 02, 2020 08:00 ET | NKMax America
SANTA ANA, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...
NKMAX_AMERICA-300x215.png
NKMax America Presents Promising Clinical Research Findings at 2020 ASCO Virtual Conference
May 29, 2020 15:19 ET | NKMax America
SANTA ANA, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell...